Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Organon & Co. (NY: OGN ) 20.35 +0.41 (+2.06%) Official Closing Price Updated: 7:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Organon & Co. < Previous 1 2 3 Next > Organon Reports Results for the Second Quarter Ended June 30, 2024 August 06, 2024 From Organon & Co. Via Business Wire Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024 July 09, 2024 From Organon & Co. Via Business Wire European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 May 24, 2024 From Organon & Co. Via Business Wire Organon Announces Pricing of $1.0 Billion Senior Notes Offering May 07, 2024 From Organon & Co. Via Business Wire Organon Announces Proposed $1.0 Billion Senior Notes Offering May 07, 2024 From Organon & Co. Via Business Wire Organon Reports Results for the First Quarter Ended March 31, 2024 May 02, 2024 From Organon & Co. Via Business Wire Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 April 08, 2024 From Organon & Co. Via Business Wire Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints April 08, 2024 From Organon & Co. Via Business Wire Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary February 20, 2024 From Organon & Co. Via Business Wire Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023 February 15, 2024 From Organon & Co. Via Business Wire Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024 February 01, 2024 From Organon & Co. Via Business Wire Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older January 10, 2024 From Organon & Co. Via Business Wire Merck, the Dow's hottest stock, gets set to report Q4 financials January 08, 2024 Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. Via MarketBeat Topics Stocks Exposures US Equities Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook January 08, 2024 From Organon & Co. Via Business Wire Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From Organon & Co. Via Business Wire Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines December 18, 2023 From Organon & Co. Via Business Wire Organon To Present at the Piper Sandler 35th Annual Healthcare Conference November 21, 2023 From Organon & Co. Via Business Wire Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira® November 07, 2023 From Samsung Bioepis Via GlobeNewswire Organon Reports Results for the Third Quarter Ended September 30, 2023 November 02, 2023 From Organon & Co. Via Business Wire Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed November 01, 2023 From Organon & Co. Via Business Wire Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023 October 19, 2023 From Organon & Co. Via Business Wire Lululemon Athletica Races to New High with S&P 500 Entry October 17, 2023 Lululemon's stock soared 10.31%, its best level since late 2021, upon joining the S&P 500, replacing Activision Blizzard. The change is effective October 18. Via MarketBeat Topics Stocks Exposures US Equities Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice September 27, 2023 From Organon & Co. Via Business Wire First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology September 14, 2023 From Organon & Co. Via Business Wire Organon Bolsters Research & Development Expertise with Two Leadership Appointments September 05, 2023 From Organon & Co. Via Business Wire Organon Reports Results for the Second Quarter Ended June 30, 2023 August 08, 2023 From Organon & Co. Via Business Wire Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar August 01, 2023 From Samsung Bioepis Via GlobeNewswire Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023 July 17, 2023 From Organon & Co. Via Business Wire REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator July 05, 2023 From Organon Via Business Wire Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator July 01, 2023 From Organon & Co. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.